Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection

Chinese Medicine - Tập 18 Số 1
Rui Zheng1, Chunxia Zhao2, Zhiyue Guan1, Herong Cui1, Hongcai Shang1
1Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Haiyuncang Lane 5, Dongcheng District, Beijing, 100700, China
2Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Dongcheng District, Beijing, China

Tóm tắt

Abstract Background Age and herb-drug combination are risk factors for the severity of Xiyanping injection (XYP) associated adverse events (AEs). Objective To analyze risk factors contributing to the severity of XYP’s AEs using a variable importance for projection (VIP) method. Methods AEs related to the use of XYP were extracted from the China National Adverse Drug Reaction Monitoring Information System (2004–2017) and classified as general or severe. Data were analyzed with respect to age and 12 herb-drug combinations, including ribavirin (RB), ceftriaxone, penicillin sodium, ambroxol hydrochloride (AH), clindamycin, cefoxitin sodium, azithromycin (AZM), ceftazidime, amoxicillin sodium/potassium clavulanate, levofloxacin hydrochloride, sodium cefazolin pentahydrate, and acyclovir according to VIP scores and correlation coefficient (Coeff). Results A total of 21,714 AEs (general 20,660; severe 1054) related to XYP combinations were included. Using XYP alone tended to produce general AEs (All VIP = 3.124; 1.329; 1.857; 2.169; 2.400, Coeff < 0). For all set, 0–6 years old patients tend to have general AEs (VIP = 2.425, Coeff < 0), while those > 41 years old patients tend to have severe AEs (VIP = 1.180; 2.323, Coeff > 0). For 0–40 years old patients, XYP-RB combination had a greater impact on the severity of AEs (VIP = 1.158; 1.360; 1.147, Coeff > 0). For 7–17 years old patients, XYP-AZM combination tended to produce general AEs (VIP = 1.502, Coeff < 0). In individuals > 65 years old, XYP-AH combination tended to result in severe AEs (VIP = 1.232, Coeff > 0). Conclusions VIP method was expected to effectively analyze risk factors in affecting the severity of AEs and control AEs more effectively. Age is the key factor contributing to the severity of AEs, and there are different influence directions. It is recommended that clinicians pay closer attention to the metabolic characteristics of different age groups. It is safe to use XYP alone and strictly implementing standardized operations such as medication interval and flushing will avoid undesired AEs.

Từ khóa


Tài liệu tham khảo

Yang QW, Li Q, Zhang J, Xu Q, Yang X, Li ZY, et al. Crystal structure and anti-inflammatory and anaphylactic effects of andrographlide sulphonate E in Xiyanping, a traditional Chinese medicine injection. J Pharm Pharmacol. 2019;71(2):251–9. https://doi.org/10.1111/jphp.13028.

Wu MN, Zhou LJ, Zhou DM. Xiyanping injection combined with acitretin for psoriasis vulgaris: a systematic review and meta-analysis. Front Pharmacol. 2022;13:971715. https://doi.org/10.3389/fphar.2022.971715.

Chen X, Kang F, Lai J, Deng X, Guo X, Liu S. Comparative effectiveness of phlegm-heat clearing Chinese medicine injections for AECOPD: a systematic review and network meta-analysis. J Ethnopharmacol. 2022;292:115043. https://doi.org/10.1016/j.jep.2022.115043.

Wu M, Zhou L, Zhou D. Xiyanping injection combined with acitretin for psoriasis vulgaris: a systematic review and meta-analysis. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.971715.

Zhang XY, Lv L, Zhou YL, Xie LD, Xu Q, Zou XF, et al. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res. 2021;35:4401–10. https://doi.org/10.1002/ptr.7141.

Tong X, Zhu X, Wang C, Zhou Y, Yan Y, Zhan S, et al. Concomitant medication use with xiyanping injection and the risk of suspected allergic reactions: a nested case-control study based on China’s national medical insurance database. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.883407.

Zheng R, Tao L, Kwong JSW, Zhong C, Li C, Chen S, et al. Risk factors associated with the severity of adverse drug reactions by Xiyanping injection: A propensity score-matched analysis. J Ethnopharmacol. 2020;250:112424. https://doi.org/10.1016/j.jep.2019.112424.

Zheng R, Sun Y, Zhang X, Zhao C, Wang P, Chen S, et al. Clinical features of adverse events associated with Xiyanping-Ribavirin combination: A systematic review. J Ethnopharmacol. 2022;292:115076. https://doi.org/10.1016/j.jep.2022.115076.

Wold S, Johansson E, Cocchi M. PLS: partial least squares projections to latent structures[M]. 3D QSAR in Drug Design: Theory, Methods and Applications. Kluwer ESCOM Science Publisher, 1993;523–550.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9. https://doi.org/10.1016/S0140-6736(00)02799-9.

Akarachantachote N, Chadcham S, Saithanu K. Cutoff threshold of variable importance in projection for variable selection. Int J Pure Appl Math. 2014;94:307–22.

Farrés M, Platikanov S, Tsakovski S, Tauler R. Comparison of the variable importance in projection (VIP) and of the selectivity ratio (SR) methods for variable selection and interpretation. J Chemom. 2015;29:528–36.

Oussama A, Elabadi F, Platikanov S, Kzaiber F, Tauler R. Detection of olive oil adulteration using FT-IR spectroscopy and PLS with variable importance of projection (VIP) scores. J Am Oil Chem Soc. 2012;89:1807–12.

Rajalahti T, Kvalheim OM. Multivariate data analysis in pharmaceutics: a tutorial review. Int J Pharm. 2011;417:280–90. https://doi.org/10.1016/j.ijpharm.2011.02.019.

Zhang YH, Xia ZN, Qin LT, Liu SS. Prediction of blood-brain partitioning: a model based on molecular electronegativity distance vector descriptors. J Mol Graph Model. 2010;29:214–20. https://doi.org/10.1016/j.jmgm.2010.06.006.

Lee J, Chang K, Jun C, Cho R, Chung H, Lee H. Kernel-based calibration methods combined with multivariate feature selection to improve accuracy of near-infrared spectroscopic analysis. Chemom Intell Lab Syst. 2015;147:139–46.

Sisay T, Wami R. Adverse drug reactions among major depressive disorders: patterns by age and gender. Heliyon. 2021;7:e8655. https://doi.org/10.1016/j.heliyon.2021.e08655.

Kunnoor NS, Devi P, Kamath DY, Anthony N, George J. Age- and gender-related differences in drug utilisation and adverse drug reaction patterns among patients in a coronary care unit. Singapore Med J. 2014;55:221–8. https://doi.org/10.11622/smedj.2014056.

Bégaud B, Fourrier KMA. Does age increase the risk of adverse drug reactions? Br J Clin Pharmacol. 2019;5:550–2.

Qing LI, Beibei LI, Wenke Z. Clinical surveillance cases of clinical safety in 296 200 cases of traditional Chinese medicine injection: a systematic review. Chin J Evid Based Med. 2019;19:28–35.

National medical products administration. National Adverse drug reaction monitoring annual report. 2021. https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20220329161925106.html.

Quinn KM, Hussain T, Kraus F, Formosa LE, Lam WK, Dagley MJ, et al. Metabolic characteristics of CD8+ T cell subsets in young and aged individuals are not predictive of functionality. Nature Communications. 2020. https://doi.org/10.1038/s41467-020-16633-7.

de Saskia NW. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol. 2011;7:935–48. https://doi.org/10.1517/17425255.2011.577739.

Yan M. Clinical value of Xiyanping injection in the treatment of upper respiratory tract infection in children. Guide of China Medicine. 2020;18:154–5.

Mingxing M, Xuefeng W, Xiuying Z, Linfeng L, Lichao S, Xinran F. Meta analysis of the efficacy and safety of Xiyanping injection in the treatment of viral pneumonia in children. Jiangxi traditional Chinese Medicine. 2020;51:41–6.

Qiang L, Shu Z. Analysis of 270 cases of adverse drug reactions/events reports caused by xiyanping injection. Pharmacovigil China. 2012;9:751–4.

Li X, Li S, Xu Y, Wei D, Shi Q, Zhu Q, et al. Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: a prospective, randomized, controlled trial. Chin J Integr Med. 2017;23:887–92. https://doi.org/10.1007/s11655-016-2504-3.

Tan L, Li M, Lin Y. Safety concerns of traditional chinese medicine injections used in Chinese children. Evid Based Complement Alternat Med. 2019;2019:1–10. https://doi.org/10.1155/2019/8310368.

Yan YI, Chun-ying LI, Yu-shi Z, Yong Z, Jia-yin H, Yu-ting L, et al. Evaluation and study of pseudo-allergic reactions of three kinds of traditional Chinese medicine injections and its mechanisms. Chin J Tradit Chin Med. 2015;40:2711–6.

Mulherkar S, Firozi K, Huang W, Uddin MD, Grill RJ, Costa-Mattioli M, et al. RhoA-ROCK inhibition reverses synaptic remodeling and motor and cognitive deficits caused by traumatic brain injury. Sci Rep. 2017. https://doi.org/10.1038/s41598-017-11113-3.

Han J, Zhao Y, Zhang Y, Li C, Yi Y, Pan C, et al. RhoA/ROCK signaling pathway mediates shuanghuanglian injection-induced pseudo-allergic reactions. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.00087.

Samala S, Veeresham C. Pharmacokinetic and pharmacodynamic interaction of boswellic acids and andrographolide with glyburide in diabetic rats: including its PK/PD modeling. Phytother Res. 2016;30:496–502.

Chun-xue W. Process influence in vivo of Reduning injection Co-administration. Nanjing Univ Chin Med; 2019.

Jie B. Clinical efficacy of ribavirin combined with Xiyanping in the treatment of severe hand foot mouth disease. World Latest Med Inf. 2019;19:146–7.

Rui Z, Shiqi C, Hongcai S. The safety evaluation method of herb-drug combination: manifestation-target alliance. World Sci Technol Mod Tradit Chin Med Mater Med. 2018;20:1734–8.

Thông tin
Thông tin xuất bản

Chinese Medicine

Tập 18 Số 1

Thông tin tác giả